Currently, we are building our new valuation model for VELA on this project milestone chart.

With 8 of their subsidiaries operating by year end…they look like EBITDA cash flow positive next year.

Click here to view the chart.

Plandai Biotechnology, Inc. has now closed on its INITIAL $13 million loan from the Land and Agriculture Bank of South Africa. Plandai could NOT have a better financial partner in its quest to disrupt and re-invent the $20 BILLION a year (and growing at 14% annual rate) green tea extract industry. Here is the link to www.landbank.co.za

Today's breakthrough science story of the day: RepliCel Life Sciences, Inc., (REPCF) a Vancouver BC based biotechnology company founded on 10 years of research into human hair cell extraction/replicating/re-implantation, received positive results from their first HUMAN trial of the "RepliCel Process" their patented process of extracting, replicating and injecting hair cells to regrow hair in bald patients. No serious safety issues and positive hair growth means they are now moving quickly to start a much larger, dosing trial with over 100 patients.

NBT Equities Research LLC is working on a complete updated research report on VelaTel Global Communications, Inc.  (VELA). We need to update valuations on the various subsidiaries of the VELA holding company to the new 2012-2017 pro-forma revenue/subscriber/EBITA forecasts.